During Tuesday’s Morning trade, Shares of ConAgra Foods Inc (NYSE:CAG), lost -1.68% to $41.65.
A new study conducted by Creighton University and presented at the Academy of Nutrition and Dietetics’ 2015 Food & Nutrition Conference & Expo (FNCE) shows that selecting a high protein breakfast, like egg whites, may not only affect how full and satisfied young women feel during the morning, but may assist them eat less throughout the entire day.
The study found that college-age women ate 10 percent fewer calories daily when they ate a protein-rich egg white breakfast made with Egg Beaters Original instead of toaster pastries. They also raised their daily protein intake by 24 percent and felt more full and satisfied. Egg Beaters® is simply the egg minus the yolk and provides complete, high-quality protein without the fat and cholesterol of whole eggs.
These findings build on previous research showing that egg whites – with the same calories and twice the volume of whole eggs – are an excellent choice for breakfast, as they assist people feel more satisfied than a whole egg breakfast.
This research was supported by ConAgra Foods, Inc. (CAG). For more information about the studies, visit www.ConAgraFoodsScienceInstitute.com. Visit www.EggBeaters.com for quick and easy recipe ideas.
On other hand, RBC Capital restated their sector perform rating on shares of ConAgra Foods (CAG) in a research note released on Thursday, Analyst Ratings Network.com reports.
The business also revealed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be paid a dividend of $0.25 per share. The ex-dividend date of this dividend is Wednesday, October 28th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.36%.
ConAgra Foods, Inc. operates as a food company primarily in North America. The company operates through three segments: Consumer Foods, Commercial Foods, and Private Brands. The Consumer Foods segment provides branded food products in various categories, such as meals, entrees, condiments, sides, snacks, and desserts to various retail channels, such as frozen, refrigerated, and shelf-stable temperature classes.
Shares of Brookdale Senior Living, Inc. (NYSE:BKD), declined -3.05% to $24.43, during its current trading session.
Brookdale Senior Living, declared that its Board of Directors has designated Daniel A. Decker as a Class I director and as the Non-Executive Chairman of the Board, effective October 1, 2015. Mr. Decker will fill the vacancy on the Board resulting from the recent passing of Granger Cobb.
Mr. Decker has been investing in the senior living industry for more than 20 years. During that period, he has been involved in the investment, through one private and four public companies, of about $2.5 billion of assets across a spectrum of independent living, assisted living, memory care, and skilled nursing communities and operations. His recent investments comprise joining with KKR and Beecken Petty O’Keefe & Company to acquire the operations of Sunrise Senior Living in 2013. During his career, Mr. Decker has served on the boards of several REITs and senior housing companies, counting Omega Healthcare Investors, Inc. (where he served as Executive Chairman and then as Chairman of the Board), Sentio Healthcare Properties, Inc., Health Care REIT, Inc. and Forum Group, Inc.
On other hand, In a research note released to the investors, JMP Securities maintains its rating on Brookdale Senior Living Inc. (NYSE:BKD).The analysts at the brokerage house have a current rating of Market Outperform on the shares. In a recent information released to the investors, JMP Securities lowers the new price target from $44 per share to $36 per share. The rating by the firm was issued on September 23, 2015.
Brookdale Senior Living Inc. owns and operates senior living communities in the United States. It operates through five segments: Retirement Centers, Assisted Living, Ongoing Care Retirement Communities (CCRCs)Rental, Brookdale Ancillary Services, and Administration Services.
Shares of Lockheed Martin Corporation (NYSE:LMT), dipped -0.03%, and is now trading at $211.66.
Lockheed Martin, started production of a new generation of modular high power lasers this month. The first laser built using the modular technique will be a 60-kilowatt system for a U.S. Army vehicle.
Production of the fiber modules laser will take place at Lockheed Martin’s Bothell, Washington facility. The modular laser design allows the laser power to be varied across an extremely wide range according to the needs of a specific mission and threat. Its incorporation of commercial fiber laser components into easily reproduced modules makes production of Lockheed Martin’s laser highly affordable. The Army has the option to add more modules and improvement power from 60kW to 120kW as a result of the laser’s modularity.
On other hand, Lockheed Martin (LMT) has received a consensus rating of “Buy” from the fifteen analysts that are presently covering the company, ARN reports. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $217.29.
Lockheed Martin Corporation, a security and aerospace company, engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services.
Finally, Shares of Boston Scientific Corporation (NYSE:BSX), lost -2.81%, and is now trading at $16.59.
Boston Scientific, has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
On other hand, Shares of Boston Scientific (BSX) have earned a consensus recommendation of “Buy” from the twenty-four brokerages that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $19.39.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
